Healthcare
Trevena, Inc.(TRVN)
Live Price
Offline$0.001
-90.91% today
1Y Change
-99.91%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- +847.6%
- EPS Growth
- +58.4%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Trevena, Inc. (TRVN) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.9% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +847.6%, EPS growth of +58.4%, a dividend yield of 0.0%. What stands out right now is revenue +847.6%, EPS +58.4%, free cash flow +35.8% with operating margin -1129.2% and ROIC -103.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TRVN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+847.6% vs +7.6% peer median
Operating Margin
Below sector median
-1129.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +847.6% and EPS at +58.4%, with operating margin around -1129.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Feb 25, 2026 | โ | +0.0% | +0.0% | +81.8% |
2025 Nov 5, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRVN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TRVN Max Drawdown
-99.91%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TRVN and SPY.
Company Overview
Trevena, Inc.
Other OTC
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
- Leadership
- Carrie L. Bourdow
- IPO Date
- Jan 31, 2014
- Employees
- 23
- Street Address
- 955 Chesterbrook Boulevard
- Mailing
- Chesterbrook, PA, 19087
- Region
- Chesterbrook, PA, US
- Reporting Currency
- USD
- Investor Line
- 610 354 8840
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- โ
Growth
- Revenue
- +847.6%
- EPS
- +58.4%
- Free Cash Flow
- +35.8%
Profitability
- Gross Margin
- 46.6%
- Operating Margin
- -1129.2%
- Net Margin
- -1289.2%
- ROE
- -1014.6%
- ROIC
- -103.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 4.66
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.